🎙️ JLS Fund Podcast: Kenneth Shinozuka in conversation with William Leonard Pickard**
🚀 **Background on Kenneth Shinozuka** Stanford postdoctoral researcher studying psychedelic neuroscience, with a focus on ibogaine, traumatic brain injury, PTSD, addiction, veterans, and consciousness. His path into science began as a teenager, when he invented a wearable sensor to help care for his grandfather with Alzheimer’s.
🧠 **Ibogaine, Trauma & the Brain** Shinozuka discusses Stanford research showing striking improvements in PTSD, depression, anxiety, cognitive function, and disability among Special Operations veterans following ibogaine treatment—and why larger controlled studies are still needed.
🌀 **The Ibogaine Experience** Often described as a dreamlike life review, ibogaine can surface buried memories, childhood trauma, and guilt. The conversation explores why this intense confrontation with the past may be central to its therapeutic potential.
🧬 **How Ibogaine Changes the Brain** From the default mode network and dopamine pathways to “matrix pharmacology,” Shinozuka explains what scientists are beginning to understand about ibogaine—and how much remains mysterious.
⚡ **Addiction, Ordeal & Transformation** Pickard and Shinozuka explore why profound healing may sometimes require an ordeal. They discuss addiction, catharsis, the “long night of the soul,” and whether confronting suffering is part of what makes psychedelics transformative.
🌍 **Bwiti Tradition & Spirituality** The discussion turns to iboga’s roots in Bwiti traditions in Gabon and what Western psychedelic medicine might learn from Indigenous approaches to ceremony, music, preparation, and integration.
🧠 **The Mystery of Consciousness** Shinozuka explains why consciousness drew him into psychedelic neuroscience and why it remains so difficult to study. Can science measure experiences like ego death and spirituality without reducing what makes them meaningful?
⚕️ **Promise, Risk & Responsible Treatment** Ibogaine carries serious cardiac risks and requires careful screening and medical monitoring. Shinozuka also emphasizes that it is not a panacea: some experience profound change, while others see temporary or minimal benefits.
🔬 **What Science Still Needs to Prove** Despite promising early results, larger controlled trials are essential. Shinozuka explains what evidence would convince him ibogaine belongs in mainstream medicine—and what might show that the early enthusiasm was overstated.
🏆 **Final Takeaways** A wide-ranging exploration of ibogaine, trauma, addiction, neuroscience, spirituality, and consciousness—and the challenge of scientifically understanding one of psychedelics’ most mysterious compounds.
✨ **Support this work and unlock exclusive conversations with pioneers in psychedelics, neuroscience, consciousness, and frontier science on Patreon:** / thelastalchemist
🔗 **Stay tuned for more conversations exploring the ideas, science, and people reshaping our understanding of the mind and human potential.**
